Eli Lilly & Co

Discover how Eli Lilly’s clinical wins in obesity and neurology, plus strategic China‑India expansions, are driving market confidence and future growth.

Discover how Eli Lilly’s new diabetes‑obesity drug, expanded Olumiant approval, and AI‑powered LillyPod partnership are reshaping its competitive edge and investor appeal.

Explore how Eli Lilly’s $2.4 B acquisition of Orna Therapeutics boosts its in‑vivo CAR‑T platform, advancing next‑generation cell therapies and expanding oncology and immunology portfolios.

Explore how Eli Lilly’s AI‑driven obesity partnership with Nimbus Therapeutics, market‑cap momentum, and strategic pricing moves fuel its growth toward a $1 trillion milestone.

Discover how Eli Lilly’s $1 trillion valuation surge is driven by GLP‑1 drugs like Mounjaro and Zepbound, Medicare pricing moves, and strategic R&D pivots for future growth.

Explore how Eli Lilly’s $74 % price cut and eloralintide’s Phase 2 success are reshaping the obesity‑drug market, boosting shares and investor confidence.

Discover how Eli Lilly’s record Q3 earnings and a Medicare price‑cut deal for weight‑loss drugs are propelling the company’s stock and reshaping the U.S. obesity‑drug market.

Eli Lilly & Co.’s stock price declined sharply after a study revealed disappointing results for its experimental weight-loss pill, Orforglipron.

Eli Lilly & Co. reported a first-quarter earnings miss, sending its stock plummeting, amidst intense competition and strategic challenges in the weight-loss drug market.